Drug intelligence / Profile preview

imapextide

Development stage: Phase 2
Lead developer: MBX Biosciences
Modality: Peptides
Administration: Subcutaneous

Overview

Imapextide (MBX 1416) is a precision peptide therapy developed by MBX Biosciences for endocrine and metabolic disorders. It is currently being investigated for the treatment of obesity and postbariatric hypoglycemia. The intellectual property underpinning imapextide was exclusively licensed from Indiana University Research and Technology Corporation.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on imapextide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on imapextide.

Explore the full profile